BioSpace News Archive

Detection of genomic alterations that drive the growth and spread of the tumor can guide treatment decisions for cancer therapies, including available biomarker driven treatments FoundationOne ® CDx analyzes substitutions, insertion and deletion alterations (indels), and copy number alterations (CNAs) in 324 genes as well as select rearrangements and genomic signatures across all solid tumors, including the three NTRK gene fusions ( NTRK 1, NTRK 2

Akumin Inc. (NASDAQ: AKU) (TSX: AKU) (the “Issuer”), announced today that it priced a private offering (the “Private Offering”) of $400 million of aggregate principal amount of 7.00% senior secured notes due 2025 (the “Notes”). The offering of the Notes is scheduled to close on November 2, 2020 , s

FoundationOne ® CDx Receives FDA-Approval as a Companion Diagnostic for VITRAKVI®(larotrectinib) to Identify Patients with NTRK Fusions Across All Solid Tumors CAMBRIDGE, Mass.--( BUSINESS WIRE )-- Foundation Medicine, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®CDx to be used as a companion diagnostic for VITRAKVI® (larotrectinib), which is currently FDA-approved for the treatment o

CM Life Sciences, Inc. (Nasdaq: CMLFU) (the “ Company ”) today announced that holders of the Company’s units sold in its initial public offering may elect to separately trade the shares of Class A common stock and redeemable warrants included in its units commencing on or about October 26, 2020. The shares of Class A common stock and warrants that are separated will trade on The Nasdaq Capital Market (“ Nasdaq ”) under the

EXMceuticals Inc. (CSE: EXM) (FSE: A2PAW2) (the “Company” or “EXM”) announces that it has applied for a voluntary management cease trade order in accordance with National Policy 12-203 due to it not being able to file its annual financial statements and MD&A for the year ended June 30, 2020 on SEDAR within 120 days of its financial year-end. The Company requires additional time to file its annual financial statements and MD&a

XORTX Therapeutics Inc. (“XORTX” or the “Company”) (CSE: XRX) (OTCQB: XRTXF), a biopharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the results of the Company’s 2020 Annual and Special Meeting of Shareholders held today.

IntelGenx Technologies Corp. (TSX-V:IGX) (OTCQB:IGXT) (the “Company” or “IntelGenx”) is pleased to announce that it has closed a private placement (the “Offering”) to certain investors in the United States of U.S.$532,000 principal amount of 8% convertible notes due October 15, 2024 (the “Notes”).

Advanced Reimbursement Solutions LLC (ARS), a Scottsdale-based medical billing and revenue cycle management enterprise, challenged Blue Cross Blue Shield of Arizona (BCBS of AZ) for its approval and subsequent denial of a double-mastectomy patient.

ATW Tech Inc. (the “Company” or “ATWTech”) (TSX-V: ATW) provides an update on the acquisition of Semeon Analytics Inc. (the “Acquisition”) and the private placement (the “Private Placement”) that were announced on October 1, 2020. ATW Tech has decided to postpone the estimated closing date of the Acquisition and the Private Placement in order to complete the due diligence of Semeon Analytics Inc.